$BNTC

Benitec Biopharma Inc.

CIK:0001808898|SEC Filings

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating expenses
Research and development	$ 23,388	$ 18,332
General and administrative	27,804	23,433
Total operating expenses	51,192	41,765
Loss from operations	(51,192)	(41,765)
Other income (loss):
Foreign currency transaction gain (loss)	120	(71)
Interest income, net	5,569	3,286
Other expense, net	(43)	(131)
Gain on extinguishment of liabilities	0	764
Total other income, net	5,646	3,848
Net loss	(45,546)	(37,917)
Other comprehensive income:
Unrealized foreign currency translation gain (loss)	(124)	53
Total other comprehensive income (loss)	(124)	53
Total comprehensive loss	(45,670)	(37,864)
Net loss	(45,546)	(37,917)
Net loss attributable to common shareholders	$ (45,546)	$ (37,917)
Net loss per share: basic	$ (0.98)	$ (1.05)
Net loss per share: diluted	$ (0.98)	$ (1.05)
Weighted Average Number of Shares Outstanding, Basic	46,558,162	36,209,271
Weighted Average Number of Shares Outstanding, Diluted	46,558,162	36,209,271

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (45,546)	$ (37,917)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	58	66
Amortization of right-of-use assets	423	330
Gain on extinguishment of liabilities	0	(764)
Share-based compensation expense	26,410	17,426
Changes in operating assets and liabilities:
Trade and other receivables	30	197
Prepaid and other assets	(948)	(111)
Trade and other payables	3,272	(2,378)
Accrued employee benefits	126	(81)
Lease liabilities	(343)	(356)
Net cash used in operating activities	(16,518)	(23,588)
Cash flows from investing activities:
Purchase of property and equipment	(105)	(18)
Net cash used in investing activities	(105)	(18)
Cash flows from financing activities:
Proceeds from the issuance of common stock	104,495	30,460
Proceeds from exercise of pre-funded warrants, Series 2 warrants and common warrants	748	42,344
Share and warrant issuance transaction costs	(6,266)	(2,319)
Net cash provided by financing activities	98,977	70,485
Effects of exchange rate changes on cash, cash equivalents, and restricted cash	(125)	49
Net increase in cash, cash equivalents, and restricted cash	82,229	46,928
Cash, cash equivalents, and restricted cash, Beginning of period	97,857	50,929
Cash, cash equivalents, and restricted cash, End of period	180,086	97,857
Supplemental cash flow information:
Initial measurement of operating lease right-of-use assets and liabilities	0	255
Re-measurement of operating lease right-of-use assets and liabilities	$ 256	$ 666

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025
Current assets:
Cash and cash equivalents	$ 179,972	$ 97,744
Restricted cash	114	113
Trade and other receivables	4	33
Prepaid and other assets	1,595	628
Total current assets	181,685	98,518
Property and equipment, net	178	131
Deposits	55	55
Prepaid and other assets	12	28
Right-of-use assets	693	860
Total assets	182,623	99,592
Current liabilities:
Trade and other payables	4,295	1,022
Accrued employee benefits	553	426
Lease liabilities, current portion	496	354
Total current liabilities	5,344	1,802
Lease liabilities, less current portion	266	495
Total liabilities	5,610	2,297
Stockholders' equity:
Preferred stock, $0.0001 par value-5,000,000 shares authorized; no shares issued or outstanding at June 30, 2026 and June 30, 2025, respectively
Common stock, $0.0001 par value-160,000,000 shares authorized; 34,416,834 and 26,250,469 shares issued and outstanding at June 30, 2026 and June 30, 2025, respectively	3	2
Additional paid-in capital	451,695	326,308
Accumulated deficit	(273,722)	(228,176)
Accumulated other comprehensive loss	(963)	(839)
Total stockholders' equity	177,013	97,295
Total liabilities and stockholders' equity	$ 182,623	$ 99,592